Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenquizone SCHEMBL29387757 | 1.00 | HSD17B10 (0.58) | HSD17B10LMNAUSP2TNKS2ALDH1A1 | |
| SCHEMBL11134668 | 0.86 | ALDH1A1 (0.48) | HSD17B10LMNAUSP2TNKS2ALDH1A1 | |
| Fenquizone SCHEMBL7618547 | 0.85 | CA2 (0.63) | HSD17B10LMNAUSP2TNKS2ALDH1A1 | |
| SCHEMBL20369036 | 0.81 | HSD17B10 (0.46) | HSD17B10LMNAUSP2TNKS2ALDH1A1 | |
| SCHEMBL11929250 | 0.81 | TNKS2 (0.46) | HSD17B10LMNAUSP2TNKS2ALDH1A1 | |
| SCHEMBL30561858 | 0.75 | ALDH1A1 (0.67) | HSD17B10LMNAALDH1A1KDM4EKMT2A | |
| SCHEMBL5625913 | 0.75 | ALDH1A1 (0.67) | HSD17B10LMNAALDH1A1KDM4EKMT2A | |
| Quinethazone SCHEMBL301310 | 0.74 | LMNA (1.00) | HSD17B10LMNAUSP2ALDH1A1KDM4E | |
| Quinethazone SCHEMBL380450 | 0.74 | LMNA (1.00) | HSD17B10LMNAUSP2ALDH1A1KDM4E | |
| Quinethazone SCHEMBL29688344 | 0.74 | LMNA (1.00) | HSD17B10LMNAUSP2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1857 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381161-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | The George Institute for Global Health (AU) | 2023-11-30 | — | — | US | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230134747-A1 | COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | STALICLA SA (CH) | 2023-05-04 | — | — | US | claimed |
| US-20230125076-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | The George Institute for Global Health (AU) | 2023-04-27 | — | — | US | claimed |
| EP-4121034-A1 | COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Stalicla S.A. (CH) | 2023-01-25 | — | — | EP | claimed |
| WO-2021186074-A1 | COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | STALICLA SA (CH) | 2021-09-23 | — | — | WO | claimed |
| EP-3881842-A1 | COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Stalicla S.A. (CH) | 2021-09-22 | — | — | EP | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| EP-3826633-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | The George Institute For Global Health (AU) | 2021-06-02 | — | — | EP | claimed |
| WO-2021054927-A2 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2021-03-25 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003039521-A1 | SOLID, STABILIZED, PROMPT- AND/OR MODIFIED-RELEASE THERAPEUTICAL SYSTEMS FOR THE ORAL ADMINISTRATION OF LIQUID ACTIVE PRINCIPLES, EXCIPIENTS OR FOODSTUFFS | FARMATRON LTD. (GB) | 2003-05-15 | — | — | WO | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| CN-1315945-A | Nitrate salts of antihypertensive drugs | NICOX SA (FR) | 2001-10-03 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1087953-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 2001-04-04 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1999067231-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 1999-12-29 | — | — | WO | claimed |